Additionally, Icotinib, a highly selective EGFR inhibitor, has demonstrated substantial antitumor activity in advanced ESCC patients with EGFR overexpression or amplification, achieving median PFS and OS of 52 and 153 days, respectively.126. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.